VentureMed Group has filed a notice of an exempt offering of securities to raise $4,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, VentureMed Group is raising $4,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Robert Paulson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About VentureMed Group
VENTUREMED IS AN INNOVATOR in vessel preparation and drug delivery for the interventional treatment of peripheral artery disease (PAD). The companys technologies make vessel preparation simpler, quicker and more cost-effective. VentureMed offers interventionalists and their patients around the world state-of-the-art devices for treating long, complicated lesions in PAD. Founded by a vascular surgeon, VentureMed is committed to improving patient and economic outcomes.
To learn more about VentureMed Group, visit http://www.venturemedgroup.com/
Contact:
Robert Paulson, President and Chief Executive Officer
567-661-0768
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.